Publications by authors named "Anastas Kick"
Article Synopsis
- Oral semaglutide is a diabetes medication that improves blood sugar levels and has been evaluated in multiple countries through the PIONEER REAL program, focusing on its clinical and patient-reported outcomes.
- * In a pooled analysis of 1615 participants, significant reductions in glycated hemoglobin (HbA) by 1.0% and body weight by 5.0% were observed after 38 weeks of treatment, along with increased treatment satisfaction.
- * The analysis revealed that shorter duration of type 2 diabetes was associated with greater improvements in HbA and body weight, while no significant age-related effects were found on clinical outcomes.
Introduction: Real-world data provide insight into how medications perform in clinical practice. The PIONEER REAL Switzerland study aimed to understand clinical outcomes with oral semaglutide in adults with type 2 diabetes (T2D).
Methods: PIONEER REAL Switzerland was a 34-44-week, multicentre, prospective, non-interventional, single-arm study of adults with T2D naïve to injectable glucose-lowering medication who were initiated on oral semaglutide in routine clinical practice.
Case Record: The case of a 59-year-old healthy woman is described, who developed an extreme sinus bradycardia (30/min) with chest pain and acute right heart failure associated with gastrointestinal symptoms and elevation of the liver enzymes while simultaneously taking tizanidine (Sirdalud), diclofenac (Voltaren), and rofecoxib (Vioxx). The symptomatology resolved promptly after stopping the medication.
Discussion: The usual causes of sinusbradycardia like hypothyroidism, hypothermia, intracranial pressure elevation, typhoid fever, sick sinus syndrome, hyperreactive carotid sinus reflex, organic heart disease, electrolyte disorders, and pharmacotherapy with beta-blockers, digitalis, and antiarrhythmics have been excluded in this case.